NO330737B1 - Farmasoytisk preparat inneholdende insulin egnet for nasal tilforse - Google Patents

Farmasoytisk preparat inneholdende insulin egnet for nasal tilforse Download PDF

Info

Publication number: NO330737B1
Authority: NO; Norway
Prior art keywords: insulin; pharmaceutical preparation; preparation according; enhancer; value
Prior art date: 2003-12-08

Application number

NO20063135A

Other languages

English (en)

Norwegian (no)

Other versions

NO20063135L (no

Inventor

Robert J Gyurik

Carl Reppucci

Original Assignee

Cpex Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-08

Filing date

2006-07-06

Publication date

2011-06-27

2006-07-06 Application filed by Cpex Pharmaceuticals Inc filed Critical Cpex Pharmaceuticals Inc

2006-09-08 Publication of NO20063135L publication Critical patent/NO20063135L/no

2011-06-27 Publication of NO330737B1 publication Critical patent/NO330737B1/no

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 124
102000004877 Insulin Human genes 0.000 title claims abstract description 62
108090001061 Insulin Proteins 0.000 title claims abstract description 62
229940125396 insulin Drugs 0.000 title claims abstract description 62
239000000825 pharmaceutical preparation Substances 0.000 title claims description 14
230000002378 acidificating effect Effects 0.000 claims abstract description 6
238000000034 method Methods 0.000 claims abstract description 5
239000003961 penetration enhancing agent Substances 0.000 claims abstract description 4
238000002360 preparation method Methods 0.000 claims description 34
238000002425 crystallisation Methods 0.000 claims description 26
230000008025 crystallization Effects 0.000 claims description 26
239000003623 enhancer Substances 0.000 claims description 20
239000003112 inhibitor Substances 0.000 claims description 16
230000000149 penetrating effect Effects 0.000 claims description 14
FKUPPRZPSYCDRS-UHFFFAOYSA-N Cyclopentadecanolide Chemical group O=C1CCCCCCCCCCCCCCO1 FKUPPRZPSYCDRS-UHFFFAOYSA-N 0.000 claims description 13
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 10
125000000879 imine group Chemical group 0.000 claims description 10
229910052760 oxygen Inorganic materials 0.000 claims description 10
239000001301 oxygen Substances 0.000 claims description 10
239000003795 chemical substances by application Substances 0.000 claims description 8
239000007921 spray Substances 0.000 claims description 8
239000004094 surface-active agent Substances 0.000 claims description 8
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
239000000839 emulsion Substances 0.000 claims description 6
239000007788 liquid Substances 0.000 claims description 6
239000007922 nasal spray Substances 0.000 claims description 6
229940097496 nasal spray Drugs 0.000 claims description 6
229910052717 sulfur Inorganic materials 0.000 claims description 6
239000011593 sulfur Substances 0.000 claims description 6
125000000217 alkyl group Chemical group 0.000 claims description 5
230000002708 enhancing effect Effects 0.000 claims description 5
239000000126 substance Substances 0.000 claims description 4
239000008346 aqueous phase Substances 0.000 claims description 3
125000004432 carbon atom Chemical group C* 0.000 claims description 3
LXJDKGYSHYYKFJ-UHFFFAOYSA-N cyclohexadecanone Chemical compound O=C1CCCCCCCCCCCCCCC1 LXJDKGYSHYYKFJ-UHFFFAOYSA-N 0.000 claims description 3
238000009826 distribution Methods 0.000 claims description 3
150000002148 esters Chemical class 0.000 claims description 3
239000003921 oil Substances 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
229930195733 hydrocarbon Natural products 0.000 claims description 2
150000002430 hydrocarbons Chemical class 0.000 claims description 2
229910052739 hydrogen Inorganic materials 0.000 claims description 2
239000001257 hydrogen Substances 0.000 claims description 2
239000001993 wax Substances 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 42
238000009472 formulation Methods 0.000 description 25
108010075254 C-Peptide Proteins 0.000 description 18
VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 17
238000011282 treatment Methods 0.000 description 12
150000001875 compounds Chemical class 0.000 description 11
241000282887 Suidae Species 0.000 description 10
241001465754 Metazoa Species 0.000 description 9
241000282898 Sus scrofa Species 0.000 description 9
239000008280 blood Substances 0.000 description 9
210000004369 blood Anatomy 0.000 description 9
210000004379 membrane Anatomy 0.000 description 9
239000012528 membrane Substances 0.000 description 9
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
-1 cyclic lactones Chemical class 0.000 description 8
239000008103 glucose Substances 0.000 description 8
239000012744 reinforcing agent Substances 0.000 description 7
OSOIQJGOYGSIMF-UHFFFAOYSA-N cyclopentadecanone Chemical compound O=C1CCCCCCCCCCCCCC1 OSOIQJGOYGSIMF-UHFFFAOYSA-N 0.000 description 6
230000036765 blood level Effects 0.000 description 5
239000007924 injection Substances 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000000872 buffer Substances 0.000 description 4
210000004731 jugular vein Anatomy 0.000 description 4
230000035515 penetration Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
ALHUZKCOMYUFRB-UHFFFAOYSA-N 3-methylcyclopentadecan-1-one Chemical compound CC1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-UHFFFAOYSA-N 0.000 description 3
239000004743 Polypropylene Substances 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
238000010241 blood sampling Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
244000309715 mini pig Species 0.000 description 3
210000004400 mucous membrane Anatomy 0.000 description 3
239000002736 nonionic surfactant Substances 0.000 description 3
229920001155 polypropylene Polymers 0.000 description 3
239000013641 positive control Substances 0.000 description 3
230000002787 reinforcement Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
ZKVZSBSZTMPBQR-UHFFFAOYSA-N Civetone Natural products O=C1CCCCCCCC=CCCCCCCC1 ZKVZSBSZTMPBQR-UHFFFAOYSA-N 0.000 description 2
ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
206010022998 Irritability Diseases 0.000 description 2
235000019485 Safflower oil Nutrition 0.000 description 2
238000010171 animal model Methods 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
ZKVZSBSZTMPBQR-UPHRSURJSA-N civetone Chemical compound O=C1CCCCCCC\C=C/CCCCCCC1 ZKVZSBSZTMPBQR-UPHRSURJSA-N 0.000 description 2
235000012343 cottonseed oil Nutrition 0.000 description 2
239000002385 cottonseed oil Substances 0.000 description 2
150000003997 cyclic ketones Chemical class 0.000 description 2
ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
238000002224 dissection Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
210000001331 nose Anatomy 0.000 description 2
OQILCOQZDHPEAZ-UHFFFAOYSA-N octyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
206010033675 panniculitis Diseases 0.000 description 2
230000003285 pharmacodynamic effect Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
235000005713 safflower oil Nutrition 0.000 description 2
239000003813 safflower oil Substances 0.000 description 2
238000005070 sampling Methods 0.000 description 2
238000005728 strengthening Methods 0.000 description 2
210000004304 subcutaneous tissue Anatomy 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
229940042585 tocopherol acetate Drugs 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical class CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
241000282465 Canis Species 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical group OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
102000005548 Hexokinase Human genes 0.000 description 1
108700040460 Hexokinases Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000976075 Homo sapiens Insulin Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
ALHUZKCOMYUFRB-OAHLLOKOSA-N Muscone Chemical compound C[C@@H]1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-OAHLLOKOSA-N 0.000 description 1
235000019482 Palm oil Nutrition 0.000 description 1
108010076181 Proinsulin Proteins 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
239000004902 Softening Agent Substances 0.000 description 1
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
229960004676 antithrombotic agent Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000008163 avocado oil Substances 0.000 description 1
235000021302 avocado oil Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
229910052796 boron Inorganic materials 0.000 description 1
IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
229960001113 butorphanol Drugs 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
239000003093 cationic surfactant Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
HGAZMNJKRQFZKS-UHFFFAOYSA-N chloroethene;ethenyl acetate Chemical compound ClC=C.CC(=O)OC=C HGAZMNJKRQFZKS-UHFFFAOYSA-N 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
150000001923 cyclic compounds Chemical class 0.000 description 1
238000013461 design Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000004945 emulsification Methods 0.000 description 1
238000007824 enzymatic assay Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
230000004907 flux Effects 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
210000002850 nasal mucosa Anatomy 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000002540 palm oil Substances 0.000 description 1
229940023569 palmate Drugs 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
229940089513 pentadecalactone Drugs 0.000 description 1
239000012071 phase Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000005057 refrigeration Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000036280 sedation Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
239000001587 sorbitan monostearate Substances 0.000 description 1
235000011076 sorbitan monostearate Nutrition 0.000 description 1
229940035048 sorbitan monostearate Drugs 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
239000004753 textile Substances 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
210000001944 turbinate Anatomy 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Obesity (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dermatology (AREA)
Biophysics (AREA)
Hematology (AREA)
Dispersion Chemistry (AREA)
Biochemistry (AREA)
Otolaryngology (AREA)
Inorganic Chemistry (AREA)
Emergency Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

NO20063135A 2003-12-08 2006-07-06 Farmasoytisk preparat inneholdende insulin egnet for nasal tilforse NO330737B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US52772803P	2003-12-08	2003-12-08
PCT/US2004/040313 WO2005056038A1 (en)	2003-12-08	2004-12-02	Pharmaceutical compositions and methods for insulin treatment

Publications (2)

Publication Number	Publication Date
NO20063135L NO20063135L (no)	2006-09-08
NO330737B1 true NO330737B1 (no)	2011-06-27

Family

ID=34676771

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20063135A NO330737B1 (no)	2003-12-08	2006-07-06	Farmasoytisk preparat inneholdende insulin egnet for nasal tilforse

Country Status (18)

Country	Link
US (4)	US7112561B2 (de)
EP (2)	EP2241326A1 (de)
JP (2)	JP2007513199A (de)
KR (1)	KR100978717B1 (de)
CN (2)	CN101829319A (de)
AT (1)	ATE474591T1 (de)
AU (2)	AU2004296784B2 (de)
BR (1)	BRPI0418589A (de)
CA (1)	CA2547990C (de)
DE (1)	DE602004028284D1 (de)
DK (1)	DK1706128T3 (de)
EA (1)	EA010885B1 (de)
ES (1)	ES2348303T3 (de)
IL (1)	IL176015A (de)
NO (1)	NO330737B1 (de)
NZ (2)	NZ578735A (de)
WO (1)	WO2005056038A1 (de)
ZA (1)	ZA200604683B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2001244391B9 (en) *	2000-04-03	2006-10-05	Ventaira Pharmaceuticals, Inc.	Devices and formulations
EP1343521A2 (de) *	2000-12-01	2003-09-17	Battelle Memorial Institute	Verfahren zur stabilisierung von biomolekülen (z.b. insulin) in flüssigen formulierungen
US7244703B2 (en)	2001-06-22	2007-07-17	Bentley Pharmaceuticals, Inc.	Pharmaceutical compositions and methods for peptide treatment
JP2007513199A (ja) *	2003-12-08	2007-05-24	ベントレーファーマスーティカルス，インコーポレイテッド	インスリン治療のための薬学的組成物及び方法
US20060286510A1 (en) *	2005-06-15	2006-12-21	Boghosian Alan A	Method of preparing dentition for the taking of a dental impression
US10835351B2 (en)	2005-06-15	2020-11-17	Alan Ara BOGHOSIAN	Method of preparing dentition for the taking of a dental impression
US10231805B2 (en)	2005-06-15	2019-03-19	Alan Ara BOGHOSIAN	Method of preparing dentition for the taking of a dental impression
WO2007056068A2 (en) *	2005-11-02	2007-05-18	Bentley Pharmaceuticals, Inc.	Macrocyclic formulations for transmembrane drug delivery
EP2035031A4 (de) *	2006-06-08	2010-02-24	Cpex Pharmaceuticals Inc	Insulinzusammensetzung
US20080107735A1 (en) *	2006-11-02	2008-05-08	Gyurik Robert J	Macrocyclic formulations for transmembrane drug delivery
ES2579229T3 (es)	2007-03-13	2016-08-08	Jds Therapeutics, Llc	Procedimientos y composiciones para la liberación sostenida de cromo
WO2009002867A2 (en)	2007-06-26	2008-12-31	Nutrition 21, Inc.	Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
EP2282725A4 (de) *	2008-06-05	2012-07-04	Cpex Pharmaceuticals Inc	Nasalformulierungen von insulin
US20100160214A1 (en) *	2008-12-22	2010-06-24	Serenity Pharmaceuticals Corporation	Desmopressin composition
SG10201509152VA (en)	2008-12-22	2015-12-30	Allergan Inc	Intranasal desmopressin administration
CA2765221C (en)	2009-06-18	2017-10-03	Allergan, Inc.	Safe desmopressin administration
US20110097363A1 (en) *	2009-10-22	2011-04-28	Cpex Pharmaceuticals, Inc.	Therapeutically Effective Preparations of Insulin
AU2012223282B2 (en)	2011-03-01	2017-02-02	Nutrition 21, Llc	Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
EP3024473A1 (de)	2013-07-23	2016-06-01	Allergan, Inc.	Verfahren und zusammensetzungen mit desmopressin in kombination mit einem 5-alpha-reduktase-hemmer
CN105579057A (zh)	2013-07-23	2016-05-11	阿勒根公司	包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物
CA2967390A1 (en)	2014-11-20	2016-05-26	Allergan, Inc.	Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist
AU2017217466A1 (en)	2016-02-11	2018-08-23	Nutrition 21, Llc	Chromium containing compositions for improving health and fitness

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4211766A (en) *	1972-07-10	1980-07-08	Ab Bonnierforetagen	Cancer associated polypeptide antigen compositions
GB1472793A (en)	1974-03-28	1977-05-04	Ici Ltd	Pharmaceutical compositions
US4153689A (en) *	1975-06-13	1979-05-08	Takeda Chemical Industries, Ltd.	Stable insulin preparation for nasal administration
GB1554157A (en) *	1975-06-13	1979-10-17	Takeda Chemical Industries Ltd	Stable insulin preparation for intra nasal administration
GB2002795B (en)	1977-07-15	1982-03-17	Mallinckrodt Inc	Nail enamel compositions their preparation and use
US5132459A (en) *	1979-08-22	1992-07-21	Sandoz Ltd.	Propenylamines, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
CY1410A (en) *	1979-08-22	1988-04-22	Sandoz Ag	Propenylamines, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
FR2502951B1 (fr)	1981-04-06	1985-12-06	Sandoz Sa	Compositions pharmaceutiques topiques sous forme d'une micro-emulsion
DE3264693D1 (en) *	1981-12-24	1985-08-14	Ciba Geigy Ag	Cyclic octapeptides and pharmaceutical compositions thereof, and processes for their production and use
US4659696A (en)	1982-04-30	1987-04-21	Takeda Chemical Industries, Ltd.	Pharmaceutical composition and its nasal or vaginal use
JPS59163313A (ja) *	1983-03-09	1984-09-14	Teijin Ltd	経鼻投与用ペプチドホルモン類組成物
US4912124A (en)	1984-02-23	1990-03-27	Ortho Pharmaceutical Corporation	Antifungal dermatological solution
US4760096A (en) *	1985-09-27	1988-07-26	Schering Corporation	Moisturizing skin preparation
DE3687458T2 (de)	1985-11-04	1993-07-29	Owen Galderma Lab Inc	Filmbildende arzneimitteltraeger zur verabreichung von arzneimitteln an naegeln
US5023252A (en) *	1985-12-04	1991-06-11	Conrex Pharmaceutical Corporation	Transdermal and trans-membrane delivery of drugs
EP0248885B1 (de) *	1985-12-04	1992-08-05	HSIEH, Dean	Transdermale verabreichung von arzneimitteln
US5731303A (en)	1985-12-04	1998-03-24	Conrex Pharmaceutical Corporation	Transdermal and trans-membrane delivery compositions
DE3544983A1 (de) *	1985-12-19	1987-06-25	Hoechst Ag	Antimykotisch wirksamer nagellack
CA1291036C (en) *	1986-04-23	1991-10-22	Edwin I. Stoltz	Nasal administration of drugs
US4782059A (en)	1986-09-29	1988-11-01	Merck & Co., Inc.	Method of controlling mycotic infections and compositions therefor
US4894375A (en) *	1986-09-29	1990-01-16	Merck & Co., Inc.	Method of controlling mycotic infections and compositions therefor
US5179079A (en) *	1986-12-16	1993-01-12	Novo Nordisk A/S	Nasal formulation and intranasal administration therewith
HU200914B (en)	1987-03-09	1990-09-28	Horvath Gyoengyi Lengyelne	Process for producing new medical dosage unit suitable for local treatment of fungus infection of nails
US5641475A (en) *	1987-05-15	1997-06-24	Tristrata, Inc.	Antiodor, antimicrobial and preservative compositions and methods of using same
DE3720147A1 (de)	1987-06-16	1988-12-29	Hoechst Ag	Antimykotisch wirksamer nagellack sowie verfahren zu dessen herstellung
LU86924A1 (fr)	1987-06-19	1989-03-08	Oreal	Vernis a ongles anhydres
US4983393A (en) *	1987-07-21	1991-01-08	Maximed Corporation	Intra-vaginal device and method for sustained drug release
US4789660A (en) *	1987-09-10	1988-12-06	American Home Products Corporation	Insulin administration using methyl and propyl paraben
US5028431A (en) *	1987-10-29	1991-07-02	Hercon Laboratories Corporation	Article for the delivery to animal tissue of a pharmacologically active agent
ATE70446T1 (de)	1988-01-13	1992-01-15	Sanol Arznei Schwarz Gmbh	Konzentrierte corticosteroide enthaltende loesungen und verfahren zu deren herstellung.
US5656286A (en) *	1988-03-04	1997-08-12	Noven Pharmaceuticals, Inc.	Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4920109A (en) *	1988-04-18	1990-04-24	Merck & Co., Inc.	Antifungal compositions and method of controlling mycotic infections
US4920112A (en) *	1988-04-18	1990-04-24	Merck & Co., Inc.	Fungicidal compositions and method
US5160737A (en)	1988-05-03	1992-11-03	Perio Products Ltd.	Liquid polymer composition, and method of use
US5116603A (en) *	1989-01-31	1992-05-26	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Oral antifungal preventative, and method of use
CA2008775C (en) *	1989-02-24	1998-12-22	Alberto Ferro	Nail lacquer
HUT58201A (en)	1989-03-03	1992-02-28	Sandoz Ag	Process for producing antiphlogistic pharmaceutical composition containing naphtalene-methan-amino derivatives
FR2646603B1 (fr)	1989-05-03	1991-07-12	Oreal	Composition nettoyante
US5214046A (en) *	1989-07-27	1993-05-25	Hoffmann-La Roche Inc.	Substituted aminoalkoxybenzene anti-fungicidal compositions and use
CA2020888A1 (en) *	1989-07-27	1991-01-28	Philippe Guerry	Substituted aminoalkoxybenzene derivatives
US5562608A (en)	1989-08-28	1996-10-08	Biopulmonics, Inc.	Apparatus for pulmonary delivery of drugs with simultaneous liquid lavage and ventilation
DE69115602T3 (de)	1990-07-04	2000-08-03	Kao Corp	Haarbehandlungszusammensetzung
JPH078806B2 (ja)	1990-08-16	1995-02-01	旭化成工業株式会社	カルシトニン類含有経鼻投与用乳剤
FR2666962B1 (fr)	1990-09-26	1996-06-14	Oreal	Composition antifongique sous forme de spray sec.
IT1247138B (it) *	1991-03-06	1994-12-12	Dompe Farmaceutici Spa	Composizione farmaceutica idrofila contenente ketoprofene sale di lisina per uso topico.
FR2673537B1 (fr)	1991-03-08	1993-06-11	Oreal	Utilisation d'agents de penetration hydrophiles dans les compositions dermatologiques pour le traitement des onychomycoses, et compositions correspondantes.
US5437272A (en) *	1991-05-01	1995-08-01	Alliance Pharmaceutical Corp.	Perfluorocarbon associated gas exchange
EP0583358B1 (de) *	1991-05-03	1998-12-02	Alliance Pharmaceutical Corporation	Partielle Flüssigkeitsbeatmung mittels Fluorkohlenwasserstoffen
HU223343B1 (hu)	1991-05-20	2004-06-28	Novartis Ag.	Allil-amin-származékot tartalmazó gyógyászati készítmények és eljárás azok előállítására
US6005001A (en)	1991-05-20	1999-12-21	Novartis Ag (Formerly Sandoz Ag)	Pharmaceutical composition
HU219480B (hu)	1991-05-23	2001-04-28	Novartis Ag.	Eljárás gombás körömmegbetegségek ellen helyileg alkalmazható, allil-amin-származékot tartalmazó gyógyászati készítmények előállítására
GB9111611D0 (en) *	1991-05-30	1991-07-24	Sandoz Ltd	Liposomes
TW246682B (de)	1991-08-12	1995-05-01	Procter & Gamble
DE69226372T2 (de) *	1991-11-14	1999-04-01	Alliance Pharmaceutical Corp., San Diego, Calif.	Vorrichtung zur teilweisen flüssigen beatmung mit fluorkohlenwasserstoffen
DE4242919A1 (de)	1992-12-18	1994-06-23	Boehringer Mannheim Gmbh	Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
US5888477A (en) *	1993-01-29	1999-03-30	Aradigm Corporation	Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
IT1261776B (it) *	1993-03-12	1996-06-03	Mendes Srl	Uso di terbinafina per il trattamento terapeutico della pneumocistosi.
US6191105B1 (en)	1993-05-10	2001-02-20	Protein Delivery, Inc.	Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5514670A (en) *	1993-08-13	1996-05-07	Pharmos Corporation	Submicron emulsions for delivery of peptides
US5661170A (en) *	1994-03-21	1997-08-26	Woodward Laboratories, Inc.	Antimicrobial compositions and methods for using the same
JP3081766B2 (ja) *	1994-05-06	2000-08-28	東興薬品工業株式会社	角質貯留型抗真菌外用組成物
FR2722102B1 (fr) *	1994-07-11	1996-08-23	Cird Galderma	Utilisation de particules creuses deformables dans une composition cosmetique et/ou dermatologique, contenant des matieres grasses
JPH0827018A (ja) *	1994-07-22	1996-01-30	Sanwa Kagaku Kenkyusho Co Ltd	生理活性ペプチド又は蛋白質を含有する薬剤組成物
DE69512083T2 (de)	1994-11-17	2000-03-30	Alza Corp., Palo Alto	Vorrichtung zur erhöhung der wirkstoffsverabreichung durch elektrotransport
US5696164A (en)	1994-12-22	1997-12-09	Johnson & Johnson Consumer Products, Inc.	Antifungal treatment of nails
US5945409A (en) *	1995-03-10	1999-08-31	Wilson T. Crandall	Topical moisturizing composition and method
GB9509631D0 (en)	1995-05-12	1995-07-05	Sandoz Ltd	Antifungal combination
US5667809A (en) *	1995-06-07	1997-09-16	Alliance Pharmaceutical Corp.	Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
GB9513750D0 (en) *	1995-07-06	1995-09-06	Sandoz Ltd	Use of allylamines
FR2737118B1 (fr)	1995-07-28	1997-09-05	Oreal	Composition dermatologique ou pharmaceutique, procede de preparation et utilisation
WO1997009960A1 (en)	1995-09-14	1997-03-20	Sorenson Pharmaceutical, Inc.	Composition and method for treating diseased nails
NZ280065A (en)	1995-09-20	1998-04-27	Apotex Inc	Preparation of n-alkyl-n-(1-naphthylmethyl)alk-2-en-4-ynylamine derivatives
JP3263598B2 (ja) *	1995-11-01	2002-03-04	有限会社ドット	経鼻吸収用生理活性ペプチド組成物
KR100213465B1 (ko) *	1996-11-01	1999-08-02	최좌진	케토프로펜 패취 조성물
US5837289A (en)	1996-07-23	1998-11-17	Grasela; John C.	Transdermal delivery of medications using a combination of penetration enhancers
CA2263077A1 (en) *	1996-08-09	1998-02-19	Buckman Laboratories International, Inc.	Treatment of fungal infections using a combination of an anti-fungal compound and an n-alkyl-heterocyclic compound
US5993787A (en)	1996-09-13	1999-11-30	Johnson & Johnson Consumer Products, Inc.	Composition base for topical therapeutic and cosmetic preparations
ES2260802T3 (es) *	1996-10-18	2006-11-01	Arizona Chemical Company	Geles de poliamida terminada en esteres.
US6694975B2 (en) *	1996-11-21	2004-02-24	Aradigm Corporation	Temperature controlling device for aerosol drug delivery
US5898028A (en) *	1997-03-20	1999-04-27	Novo Nordisk A/S	Method for producing powder formulation comprising an insulin
US5813416A (en)	1997-04-03	1998-09-29	Rudolph; James M.	File with sanitizing agent
US6207142B1 (en) *	1997-04-14	2001-03-27	Janssen Pharmaceutica N.V.	Compositions containing an antifungal and a cationic agent
US6645506B1 (en)	1997-04-18	2003-11-11	Ganeden Biotech, Inc.	Topical compositions containing extracellular products of Pseudomonas lindbergii and Emu oil
US5976547A (en)	1997-04-22	1999-11-02	Niblick Pharmaceuticals, Inc.	Analgesic and antiphlogistic compositions and therapeutic wrap for topical delivery
US6482839B1 (en)	1997-06-02	2002-11-19	Cellegy Pharmaceuticals, Inc.	Pyridine-thiols for treatment of a follicular dermatosis
US6294350B1 (en) *	1997-06-05	2001-09-25	Dalhousie University	Methods for treating fibroproliferative diseases
US6165484A (en)	1997-08-26	2000-12-26	Wake Forest University	EDTA and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
EP1017427B1 (de) *	1997-08-26	2006-04-26	Board of Regents, The University of Texas System	Verwendung einer zusammensetzung die einen chelatbildner und eine antimikrobielle verbindung enthaltet zur behandlung von biofilmen
JP4503825B2 (ja)	1997-08-27	2010-07-14	カリフォルニアインスティテュートオブテクノロジー	生物学的組織において癒着の形成を防止するための方法および組成物
US5976566A (en)	1997-08-29	1999-11-02	Macrochem Corporation	Non-steroidal antiinflammtory drug formulations for topical application to the skin
US6433040B1 (en) *	1997-09-29	2002-08-13	Inhale Therapeutic Systems, Inc.	Stabilized bioactive preparations and methods of use
US5968919A (en)	1997-10-16	1999-10-19	Macrochem Corporation	Hormone replacement therapy drug formulations for topical application to the skin
KR20010031363A (ko) *	1997-10-22	2001-04-16	젠스 포니카우	진균류에 의한 점막염을 국소 치료하기 위한 항진균제의용도
US6030948A (en) *	1997-12-19	2000-02-29	Mann; Morris A.	Hair regeneration compositions for treatment of alopecia and methods of application related thereto
CA2278328C (en) *	1998-02-09	2008-07-22	Macrochem Corporation	Antifungal nail lacquer and method using same
US6200951B1 (en) *	1998-03-12	2001-03-13	Icos Corporation	Chitinase chitin-binding fragments
US6225075B1 (en) *	1998-03-13	2001-05-01	Advanced Research And Technology Institute, Inc.	DNA encoding sterol methyltransferase
US6231875B1 (en) *	1998-03-31	2001-05-15	Johnson & Johnson Consumer Companies, Inc.	Acidified composition for topical treatment of nail and skin conditions
NL1008795C2 (nl) *	1998-04-02	1999-10-05	Rene Werenfridus Lodewijk Vroo	Samenstelling voor het behandelen van hoeven en werkwijze voor het vervaardigen van de samenstelling.
BR9909668A (pt) *	1998-04-14	2000-12-19	Jomaa Hassan	Uso de compostos de organofósforo para o tratamento terapêutico e profilático de infecções
US6623732B1 (en) *	1998-05-20	2003-09-23	Highchem Company, Ltd.	Pharmaceutical formulation for nasal administration
US5942545A (en) *	1998-06-15	1999-08-24	Macrochem Corporation	Composition and method for treating penile erectile dysfunction
US6071541A (en) *	1998-07-31	2000-06-06	Murad; Howard	Pharmaceutical compositions and methods for managing skin conditions
US6117119A (en) *	1998-08-28	2000-09-12	Silipos, Inc.	Gelatinous body protection article having a therapeutic additive
GB9823246D0 (en)	1998-10-24	1998-12-16	Danbiosyst Uk	A nasal drug delivery composition
US6849263B2 (en) *	1998-12-21	2005-02-01	Generex Pharmaceutical Incorporated	Pharmaceutical compositions for buccal delivery of pain relief medications
US6294192B1 (en) *	1999-02-26	2001-09-25	Lipocine, Inc.	Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) *	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6383471B1 (en) *	1999-04-06	2002-05-07	Lipocine, Inc.	Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
EP1172105A4 (de)	1999-04-16	2002-09-04	Fujisawa Pharmaceutical Co	Pilzbestreitende zusammenstellungen
US6395300B1 (en)	1999-05-27	2002-05-28	Acusphere, Inc.	Porous drug matrices and methods of manufacture thereof
AU5936400A (en)	1999-06-04	2000-12-28	Delrx Pharmaceutical Corporation	Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
US6335023B1 (en) *	1999-06-30	2002-01-01	Ruey J. Yu	Oligosaccharide aldonic acids and their topical use
US6403063B1 (en) *	1999-07-26	2002-06-11	Kenneth I. Sawyer	Method of treating nail fungus
WO2001013956A2 (en) *	1999-08-26	2001-03-01	Ganeden Biotech, Inc.	Use of emu oil a carrier for antifungal, antibacterial, and antiviral medications
WO2001019528A1 (en) *	1999-09-15	2001-03-22	Aradigm Corporation	Pore structures for reduced pressure aerosolization
US6894026B1 (en)	2000-01-11	2005-05-17	Atossa Healthcare, Inc.	Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
US6495124B1 (en)	2000-02-14	2002-12-17	Macrochem Corporation	Antifungal nail lacquer and method using same
DE10011081A1 (de) *	2000-03-09	2001-09-13	Aventis Pharma Gmbh	Antiinfektive Wirkstoffkombinationen und ihre Verwendung zur topischen Behandlung von Pilzerkrankungen der Fuß- und Fingernägel
US6281239B1 (en) *	2000-04-12	2001-08-28	Bradley Pharmeaceuticals, Inc.	Method of treating onychomycosis
AU5967101A (en) *	2000-05-10	2001-11-20	Rtp Pharma Inc	Media milling
US6914051B1 (en) *	2000-06-28	2005-07-05	David M Allen	Penetrating antibiotic gel for soft tissue diseases
AU2001282988B2 (en) *	2000-07-26	2006-01-05	Atopic Pty Ltd	Methods for treating atopic disorders
AU2001291721A1 (en)	2000-08-25	2002-03-04	Merck Patent G.M.B.H	Powdered mannitol and mannitol-containing compositions
US20050032683A1 (en) *	2000-10-04	2005-02-10	Amento Edward P.	Methods of modulating apoptosis by administration of relaxin agonists or antagonists
EP1201738A1 (de) *	2000-10-30	2002-05-02	Pfw Aroma Chemicals B.V.	Parfümzusammensetzung die Cyclohexadecanone enthalten
DE60217066T4 (de) *	2001-02-09	2010-07-01	Genentech, Inc., South San Francisco	Kristallisierung von igf-1
ITMI20010430A1 (it) *	2001-03-02	2002-09-02	Dinamite Dipharma S P A In For	Metodo per la sintesi di terbinafina
US6878365B2 (en) *	2001-03-10	2005-04-12	James Edward Brehove	Topical application for treating toenail fungus
US6956058B2 (en) *	2001-04-26	2005-10-18	Kao Corporation	Method for improving insulin resistance
TWI331522B (en) *	2001-06-22	2010-10-11	Cpex Pharmaceuticals Inc	Pharmaceutical composition
US6602496B2 (en) *	2001-07-05	2003-08-05	Closure Medical Corporation	Adhesive treatment for tinea corporis
US6585967B2 (en) *	2001-07-05	2003-07-01	Closure Medical Corporation	Adhesive treatment for tinea cruris
US6673369B2 (en) *	2001-08-29	2004-01-06	Ranbaxy Laboratories Limited	Controlled release formulation
WO2003047503A2 (en)	2001-10-22	2003-06-12	University Of Mississippi	Delivery of medicaments to the nail
US6544950B1 (en)	2001-12-06	2003-04-08	University Of Kentucky Research Foundation	Seventeen amino acid peptide (Peptide P) for treating ischemia and reperfusion injury
US20030211995A1 (en)	2001-12-21	2003-11-13	Kokai-Kun John Fitzgerald	Methods and formulations for eradicating or alleviating staphylococcal nasal colonization using lysostaphin
KR100459275B1 (ko) *	2001-12-28	2004-12-03	주식회사유한양행	터비나핀 또는 그의 염산염의 제조방법
US6899890B2 (en) *	2002-03-20	2005-05-31	Kv Pharmaceutical Company	Bioadhesive drug delivery system
MY139721A (en)	2002-04-19	2009-10-30	Cpex Pharmaceuticals Inc	Pharmaceutical composition
US6958142B2 (en)	2002-08-02	2005-10-25	Balance Pharmaceuticals, Inc.	Nasal spray formulation and method
US20030049307A1 (en) *	2002-08-15	2003-03-13	Gyurik Robert J.	Pharmaceutical composition
EP1596756A4 (de) *	2003-01-23	2009-11-11	Supernus Pharmaceuticals Inc	Mittel zur absorptionserhöhung
WO2005017526A1 (en) *	2003-08-05	2005-02-24	The Research Foundation Of State University Of New York	Reconstitution medium for protein and peptide formulations
JP2007513199A (ja) *	2003-12-08	2007-05-24	ベントレーファーマスーティカルス，インコーポレイテッド	インスリン治療のための薬学的組成物及び方法

2004
- 2004-12-02 JP JP2006543887A patent/JP2007513199A/ja active Pending
- 2004-12-02 AU AU2004296784A patent/AU2004296784B2/en not_active Ceased
- 2004-12-02 AT AT04812757T patent/ATE474591T1/de not_active IP Right Cessation
- 2004-12-02 DE DE602004028284T patent/DE602004028284D1/de not_active Expired - Lifetime
- 2004-12-02 EA EA200601123A patent/EA010885B1/ru not_active IP Right Cessation
- 2004-12-02 CN CN201010145134A patent/CN101829319A/zh active Pending
- 2004-12-02 EP EP10153578A patent/EP2241326A1/de not_active Withdrawn
- 2004-12-02 EP EP04812757A patent/EP1706128B1/de not_active Expired - Lifetime
- 2004-12-02 DK DK04812757.5T patent/DK1706128T3/da active
- 2004-12-02 ES ES04812757T patent/ES2348303T3/es not_active Expired - Lifetime
- 2004-12-02 KR KR1020067013705A patent/KR100978717B1/ko not_active Expired - Fee Related
- 2004-12-02 US US11/002,858 patent/US7112561B2/en not_active Expired - Fee Related
- 2004-12-02 BR BRPI0418589-7A patent/BRPI0418589A/pt not_active IP Right Cessation
- 2004-12-02 CN CN2004800413009A patent/CN1913912B/zh not_active Expired - Fee Related
- 2004-12-02 NZ NZ578735A patent/NZ578735A/en not_active IP Right Cessation
- 2004-12-02 WO PCT/US2004/040313 patent/WO2005056038A1/en not_active Ceased
- 2004-12-02 CA CA2547990A patent/CA2547990C/en not_active Expired - Fee Related
- 2004-12-02 NZ NZ547587A patent/NZ547587A/xx not_active IP Right Cessation
2006
- 2006-05-30 IL IL176015A patent/IL176015A/en not_active IP Right Cessation
- 2006-06-07 ZA ZA200604683A patent/ZA200604683B/en unknown
- 2006-07-06 NO NO20063135A patent/NO330737B1/no not_active IP Right Cessation
- 2006-08-24 US US11/509,417 patent/US7651996B2/en not_active Expired - Lifetime
2008
- 2008-12-18 US US12/337,924 patent/US20090156464A1/en not_active Abandoned
2009
- 2009-07-15 JP JP2009166623A patent/JP2009292820A/ja active Pending
- 2009-11-06 US US12/614,335 patent/US8044020B2/en not_active Expired - Fee Related
2010
- 2010-09-10 AU AU2010219399A patent/AU2010219399A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EA200601123A1 (ru)	2006-10-27
ZA200604683B (en)	2007-04-25
NZ578735A (en)	2011-06-30
US8044020B2 (en)	2011-10-25
EA010885B1 (ru)	2008-12-30
AU2010219399A1 (en)	2010-09-30
WO2005056038A1 (en)	2005-06-23
CA2547990A1 (en)	2005-06-23
JP2009292820A (ja)	2009-12-17
IL176015A0 (en)	2006-10-05
DK1706128T3 (da)	2010-10-04
DE602004028284D1 (de)	2010-09-02
NZ547587A (en)	2009-09-25
NO20063135L (no)	2006-09-08
ES2348303T3 (es)	2010-12-02
KR100978717B1 (ko)	2010-08-30
EP1706128A1 (de)	2006-10-04
EP2241326A1 (de)	2010-10-20
IL176015A (en)	2010-12-30
US20100144593A1 (en)	2010-06-10
EP1706128B1 (de)	2010-07-21
BRPI0418589A (pt)	2008-01-29
CA2547990C (en)	2011-08-02
US20090156464A1 (en)	2009-06-18
US20070010425A1 (en)	2007-01-11
AU2004296784A1 (en)	2005-06-23
JP2007513199A (ja)	2007-05-24
US20050123592A1 (en)	2005-06-09
CN1913912A (zh)	2007-02-14
US7112561B2 (en)	2006-09-26
KR20060117989A (ko)	2006-11-17
EP1706128A4 (de)	2008-11-26
ATE474591T1 (de)	2010-08-15
CN101829319A (zh)	2010-09-15
HK1097464A1 (en)	2007-06-29
AU2004296784B2 (en)	2010-12-02
US7651996B2 (en)	2010-01-26
CN1913912B (zh)	2010-06-16

Legal Events

Date	Code	Title	Description
2015-07-27	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US8044020B2 (en)	2011-10-25	Pharmaceutical compositions and methods for insulin treatment
US9439952B2 (en)	2016-09-13	Rapid-acting insulin compositions
CN108295241A (zh)	2018-07-20	安全的去氨加压素给药
US7989419B2 (en)	2011-08-02	Insulin composition
US20240342407A1 (en)	2024-10-17	Intranasal desmopressin administration
HK1097464B (en)	2010-12-17	Pharmaceutical compositions and methods for insulin treatment
MXPA06006188A (en)	2007-04-20	Pharmaceutical compositions and methods for insulin treatment
AU2015261630B2 (en)	2017-09-14	Intranasal desmopressin administration
KR20110020877A (ko)	2011-03-03	인슐린의 경비형 제형